Efficacy and risks of moricizine in inducible sustained ventricular tachycardia

R. Damle, J. Levine, J. Matos, S. Greenberg, R. Brooks, W. Frumkin, Jeffrey Goldberger, A. H. Kadish

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27%) developed life- threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.

Original languageEnglish (US)
Pages (from-to)375-381
Number of pages7
JournalAnnals of Internal Medicine
Volume116
Issue number5
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Moricizine
Ventricular Tachycardia
Cardiac Arrhythmias
Telemetry
Ventricular Fibrillation
Heart Arrest
Intensive Care Units
Therapeutics

Keywords

  • Anti-arrhythmia agents
  • Arrhythmia
  • Moricizine
  • Tachycardia
  • Ventricular fibrillation

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Damle, R., Levine, J., Matos, J., Greenberg, S., Brooks, R., Frumkin, W., ... Kadish, A. H. (1992). Efficacy and risks of moricizine in inducible sustained ventricular tachycardia. Annals of Internal Medicine, 116(5), 375-381. https://doi.org/10.7326/0003-4819-116-5-375

Efficacy and risks of moricizine in inducible sustained ventricular tachycardia. / Damle, R.; Levine, J.; Matos, J.; Greenberg, S.; Brooks, R.; Frumkin, W.; Goldberger, Jeffrey; Kadish, A. H.

In: Annals of Internal Medicine, Vol. 116, No. 5, 01.01.1992, p. 375-381.

Research output: Contribution to journalArticle

Damle, R, Levine, J, Matos, J, Greenberg, S, Brooks, R, Frumkin, W, Goldberger, J & Kadish, AH 1992, 'Efficacy and risks of moricizine in inducible sustained ventricular tachycardia', Annals of Internal Medicine, vol. 116, no. 5, pp. 375-381. https://doi.org/10.7326/0003-4819-116-5-375
Damle, R. ; Levine, J. ; Matos, J. ; Greenberg, S. ; Brooks, R. ; Frumkin, W. ; Goldberger, Jeffrey ; Kadish, A. H. / Efficacy and risks of moricizine in inducible sustained ventricular tachycardia. In: Annals of Internal Medicine. 1992 ; Vol. 116, No. 5. pp. 375-381.
@article{31c00960eb684bfc94a651dc7a9b58c3,
title = "Efficacy and risks of moricizine in inducible sustained ventricular tachycardia",
abstract = "Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27{\%}) developed life- threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12{\%}) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.",
keywords = "Anti-arrhythmia agents, Arrhythmia, Moricizine, Tachycardia, Ventricular fibrillation",
author = "R. Damle and J. Levine and J. Matos and S. Greenberg and R. Brooks and W. Frumkin and Jeffrey Goldberger and Kadish, {A. H.}",
year = "1992",
month = "1",
day = "1",
doi = "10.7326/0003-4819-116-5-375",
language = "English (US)",
volume = "116",
pages = "375--381",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Efficacy and risks of moricizine in inducible sustained ventricular tachycardia

AU - Damle, R.

AU - Levine, J.

AU - Matos, J.

AU - Greenberg, S.

AU - Brooks, R.

AU - Frumkin, W.

AU - Goldberger, Jeffrey

AU - Kadish, A. H.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27%) developed life- threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.

AB - Objective: To assess the efficacy and toxicity of moricizine in treating patients with serious ventricular arrhythmias and inducible sustained ventricular tachycardia. Design: Uncontrolled clinical trial. Setting: The intensive care and telemetry units of Northwestern Memorial Hospital, St. Francis Hospital and Medical Center, and Lenox Hill Hospital. Patients: Twenty-six patients with sustained ventricular arrhythmias or hemodynamically significant nonsustained ventricular tachycardia, most of whom failed therapy with at least one class I antiarrhythmic agent. Intervention: Patients were treated with moricizine, 400 to 1000 mg/d. Measurement: Efficacy was assessed by the results of programmed ventricular stimulation done during moricizine therapy. Main Results: Seven of the 26 patients (27%) developed life- threatening ventricular proarrhythmia during moricizine loading. Three patients had incessant sustained ventricular tachycardia, two had incessant nonsustained ventricular tachycardia, one had new sustained ventricular tachycardia, and one had new cardiac arrest. One of these patients died of intractable ventricular fibrillation. No clinical or electrophysiologic variables clearly identified those at risk for proarrhythmia. Only 3 of 26 patients (12%) became noninducible on moricizine. Conclusion: Moricizine has a low rate of efficacy and carries a considerable risk for life-threatening proarrhythmia in patients with serious ventricular arrhythmias and inducible ventricular tachycardia who have failed therapy with other class I antiarrhythmic agents.

KW - Anti-arrhythmia agents

KW - Arrhythmia

KW - Moricizine

KW - Tachycardia

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=0026547647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026547647&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-116-5-375

DO - 10.7326/0003-4819-116-5-375

M3 - Article

C2 - 1736770

AN - SCOPUS:0026547647

VL - 116

SP - 375

EP - 381

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -